Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control
Ongoing
This early-phase study tests SENTI-202, a ready-made immune cell therapy, in people with certain blood cancers (like AML and MDS) that have come back or not responded to treatment. The therapy uses specially designed natural killer (NK) cells to find and attack cancer cells while…
Phase: PHASE1 • Sponsor: Senti Biosciences • Aim: Disease control
Last updated May 17, 2026 10:26 UTC